1. Home
  2. APLT vs NEPH Comparison

APLT vs NEPH Comparison

Compare APLT & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLT
  • NEPH
  • Stock Information
  • Founded
  • APLT 2016
  • NEPH 1997
  • Country
  • APLT United States
  • NEPH United States
  • Employees
  • APLT N/A
  • NEPH N/A
  • Industry
  • APLT Biotechnology: Pharmaceutical Preparations
  • NEPH Medical/Dental Instruments
  • Sector
  • APLT Health Care
  • NEPH Health Care
  • Exchange
  • APLT Nasdaq
  • NEPH Nasdaq
  • Market Cap
  • APLT 44.0M
  • NEPH 36.1M
  • IPO Year
  • APLT 2019
  • NEPH 2004
  • Fundamental
  • Price
  • APLT $0.39
  • NEPH $3.76
  • Analyst Decision
  • APLT Buy
  • NEPH Buy
  • Analyst Count
  • APLT 7
  • NEPH 1
  • Target Price
  • APLT $6.10
  • NEPH $5.00
  • AVG Volume (30 Days)
  • APLT 2.4M
  • NEPH 69.7K
  • Earning Date
  • APLT 08-06-2025
  • NEPH 08-07-2025
  • Dividend Yield
  • APLT N/A
  • NEPH N/A
  • EPS Growth
  • APLT N/A
  • NEPH N/A
  • EPS
  • APLT N/A
  • NEPH 0.08
  • Revenue
  • APLT $265,000.00
  • NEPH $15,517,000.00
  • Revenue This Year
  • APLT $1,768.13
  • NEPH $17.06
  • Revenue Next Year
  • APLT $292.85
  • NEPH $12.20
  • P/E Ratio
  • APLT N/A
  • NEPH $48.73
  • Revenue Growth
  • APLT N/A
  • NEPH 10.34
  • 52 Week Low
  • APLT $0.30
  • NEPH $1.36
  • 52 Week High
  • APLT $10.62
  • NEPH $5.00
  • Technical
  • Relative Strength Index (RSI)
  • APLT 51.68
  • NEPH 55.35
  • Support Level
  • APLT $0.32
  • NEPH $3.83
  • Resistance Level
  • APLT $0.36
  • NEPH $4.25
  • Average True Range (ATR)
  • APLT 0.03
  • NEPH 0.40
  • MACD
  • APLT 0.00
  • NEPH -0.08
  • Stochastic Oscillator
  • APLT 73.78
  • NEPH 38.77

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: